MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, today announced a £1.8m investment, led by 24Haymarket. This investment will fund first-inman trials investigating the safety and efficacy of the company’s pivotal IL-6 product.

MediSieve has developed a patented Magnetic Blood Filtration platform technology, aimed at revolutionising the treatment of blood-borne diseases. MediSieve’s mission is to provide doctors with a tool to remove harmful components from the bloodstream.

This year was without a doubt one of the most eventful for MediSieve, even with the pandemic forcing them to change the way the team works. Seeing the potential of its technology to help treat the impact of the cytokine storm commonly experienced during a severe COVID-19 infection, the Company doubled down on its research programme aimed at removing the cytokine IL-6 from the blood.

MediSieve received a £1.6 million UKRI COVID-19 grant to support the first in-human trials of this approach later this year. In addition to making significant progress in research, the team has moved out of its shared laboratory and into a new, fully dedicated laboratory to meet its R&D needs. This gives the Company full control over safety and equipment availability, increasing and improving both safety and experimental capacity. MediSieve continue actively working alongside major industry players and building the trust of the key opinion leaders – in the last few months, the Company has secured a partnership with CADFEM and has been promoted to being a Gold Company within the EIT Health Investor Network.

George Frodsham, CEO of MediSieve, said: “We are delighted to announce this funding round led by 24 Haymarket. It shows great confidence in our technology and business plan, and will enable us to kick-on in this particularly exciting phase for MediSieve.“

-Ends-

Notes to Editors

About MediSieve

MediSieve is a biotech company, developing “Magnetic Blood Filtration”, a combination of a device and a therapeutic platform of treating blood-borne diseases by removing pathogens, toxins or other targets directly from a patient’s bloodstream. From sepsis to malaria to leukaemia and viral infections, such as COVID-19, MediSieve has the ambition of providing hospitals with a tool to tackle some of mankind’s most serious diseases.

For more information, contact George Frodsham: george@medisieve.co.uk

About 24Haymarket

24Haymarket is a private capital firm focused on disruptive early stage venture and growth equity investments in the UK, investing up to £5m in a transaction. Our Investor Network includes 100+ senior business leaders combining 3,000+ years of business experience with Director-level experience in companies worth a collective £700 billion. We invested aligned, patient capital in partnership with outstanding entrepreneurs to build the UK’s industrial leaders of the future.

For more information, please visit: www.24haymarket.com

Sort by: Newest First Oldest First Most Popular Most unliked